Single-dose Crossover Study to Evaluate the Early Bronchodilating Effect of FlutiForm HFA pMDI in Adult Subjects With Mild to Moderate Asthma

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary purpose of this study is to evaluate the early bronchodilating effect of SKP FlutiForm HFA pMDI compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: SkyePharma AG
• Collaborator: Abbott
• Treatments: Fluticasone; Formoterol Fumarate; Xhance

Criteria

Inclusion Criteria:

• Subjects with documented history of mild to moderate asthma currently taking a stable dose of inhaled corticosteroid

Exclusion Criteria:

• Participation in a prior FlutiForm study

• Smoking history within the last 12 months,

• Significant, non-reversible, pulmonary disease

• Life-threatening asthma within the last year